Zacks Rank Upgrade and Earnings Estimates - Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting an upward trend in earnings estimates, which is a powerful force impacting stock prices [1] - The Zacks rating system relies on changes in a company's earnings picture, tracking EPS estimates for the current and following years through the Zacks Consensus Estimate [2] - The upgrade to a Zacks Rank 1 indicates a positive earnings outlook for Immunocore, which could favorably impact its stock price [3] Earnings Estimate Revisions and Stock Price Movement - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements [4] - Institutional investors use earnings estimates to calculate the fair value of a company's shares, and revisions in these estimates lead to buying or selling, causing stock price movements [4] - Rising earnings estimates and the consequent rating upgrade for Immunocore imply an improvement in the company's underlying business, which investors may reward by pushing the stock higher [5] Zacks Rank System and Historical Performance - The Zacks Rank system classifies stocks into five groups based on four factors related to earnings estimates, with Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7] - Immunocore's placement in the top 5% of Zacks-covered stocks, with a Zacks Rank 1, indicates superior earnings estimate revisions, making it a strong candidate for market-beating returns [10][11] Immunocore's Earnings Estimate Revisions - Immunocore is expected to earn -$0.94 per share for the fiscal year ending December 2024, representing a year-over-year change of 16.8% [8] - Over the past three months, the Zacks Consensus Estimate for Immunocore has increased by 43.7%, reflecting steady upward revisions by analysts [8] Zacks Rank System's Unique Approach - Unlike Wall Street analysts' rating systems, which tend to be overly optimistic, the Zacks rating system maintains an equal proportion of 'buy' and 'sell' ratings across its universe of over 4,000 stocks [9] - Only the top 5% of Zacks-covered stocks receive a 'Strong Buy' rating, and the next 15% receive a 'Buy' rating, making the Zacks Rank system a reliable indicator of superior earnings estimate revisions [9][10]

Stocks Added to Zacks Rank 1 (Strong Buy) List - NB Bancorp Inc (NBBK): The bank holding company for Needham Bank has seen an 11% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Omnicell Inc (OMCL): The medication management solutions provider has experienced a 20% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - ZIM Integrated Shipping Services Ltd (ZIM): The container shipping provider has seen a 35.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR): The biotechnology company has experienced a 47.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - UL Solutions Inc (ULS): The safety science services provider has seen a 7.4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

KIMMTRAK Reimbursement Agreement - KIMMTRAK (tebentafusp) has been recommended for funding through the NHS in England by NICE for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma [1] - This recommendation overturns the initial negative decision by NICE in May 2023, which the company successfully appealed in December 2023 [2] - KIMMTRAK is now funded on the NHS in England as of 02 December 2024 [4] Impact on Patients and Medical Community - KIMMTRAK is the first therapy to improve survival for HLA-A*02:01-positive metastatic or unresectable uveal melanoma, marking a major step forward for patients and their families [3] - Uveal melanoma is a very rare form of melanoma requiring different clinical management, and the option to prescribe tebentafusp represents a significant advancement for patients [3] - The recommendation highlights the power of collaboration between patients, advocates, and medical experts in advancing care for ocular melanoma [4] About KIMMTRAK and Uveal Melanoma - KIMMTRAK is a novel bispecific protein targeting gp100, a lineage antigen expressed in melanocytes and melanoma, developed using Immunocore's ImmTAC technology platform [6] - Uveal melanoma is a rare and aggressive form of melanoma affecting the eye, with up to 50% of patients developing metastatic disease and historically having no approved treatment until KIMMTRAK [5] - KIMMTRAK is indicated as monotherapy for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in multiple regions, including the US, EU, Canada, Australia, and the UK [7] Immunocore's Technology and Pipeline - Immunocore's proprietary TCR technology generates ImmTAC molecules, designed to redirect the immune system to recognize and kill cancerous cells, with potential applications in hematologic and solid tumors [9] - The company is a commercial-stage biotechnology firm pioneering the development of TCR bispecific immunotherapies (ImmTAX) for cancer, autoimmune diseases, and infectious diseases [10] - Immunocore has nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases, with KIMMTRAK being its most advanced oncology TCR therapeutic [10]

Stock Performance and Price Targets - Shares of Immunocore Holdings PLC Sponsored ADR (IMCR) gained 2 9% over the past four weeks closing at $32 83 with a potential upside of 112 8% based on the mean price target of $69 87 [1] - The mean estimate includes 15 short-term price targets with a standard deviation of $21 22 indicating variability among analysts The lowest estimate is $24 (26 9% decline) while the most optimistic target is $100 (204 6% surge) [2] - A low standard deviation suggests greater agreement among analysts which could be a good starting point for further research [7] Analysts' Price Targets and Earnings Estimates - Analysts' growing optimism over IMCR's earnings prospects is supported by strong agreement in revising EPS estimates higher which historically correlates with near-term stock price movements [9] - The Zacks Consensus Estimate for the current year increased by 44% over the past month with eight positive revisions and no negative revisions [10] - IMCR holds a Zacks Rank 1 (Strong Buy) placing it in the top 5% of over 4 000 stocks based on earnings estimate factors indicating strong potential upside [11] Limitations of Price Targets - Price targets can mislead investors as empirical research shows they rarely predict actual stock price movements accurately [5] - Analysts may set overly optimistic price targets to generate interest in stocks often influenced by business incentives rather than unbiased analysis [6] - Investors should not rely solely on price targets for investment decisions as they should be treated with skepticism [8]

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:ZIM Integrated Shipping Services Ltd. (ZIM) : This container shipping provider has seen the Zacks Consensus Estimate for its current year earnings increasing 41.7% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.9% over the last 60 days.Rush Street Interactive, Inc. (RSI) : This online casino and sports betting company has ...

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the last trading session at $34.31, gaining 11.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $72.93 indicates an 112.6% upside potential.The average comprises 15 short-term price targets ranging from a low of $24 to a high of $100, with a standard deviation of $18.74. While the lowest estimate indicates a decline of 30.1% fro ...

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November.                   Guggenheim Securities Heal ...

Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-39992 Immunocore Holdings plc (Exact name of registrant as specified in its charter) | --- | --- | |-------- ...

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus now on earl ...